Ceva completes acquisition of IDT veterinary business assets, moving closer to its 2020 objective of 50:50 bio-pharma split >
Libourne & Dessau 3rd July 2019 - Ceva Santé Animale (“Ceva”) and IDT Biologika GmbH (“IDT”) today announced that they have successfully completed the acquisition of IDT’s veterinary biopharmaceutical and R&D activities by Ceva. The product portfolio will be transferred to Ceva branding as quickly as possible. A new Global innovation center focused on swine vaccines will be created within IDT’s exiting...
Ceva Sante Animale makes Laval its global hub for innovation in the companion animal sector >
Laval, 25 June 2019 - Ceva, France’s largest veterinary biopharmaceutical company, has consolidated its investments in Mainland France, specifically in Laval, where it has established its global hub for innovation in the companion animal sector. This ultramodern campus, combining industrial, product and managerial innovation, required an investment of more than €25 million. The goal: to develop the...
Ceva Santé Animale and IDT Biologika GmbH announce agreement for Ceva to acquire the IDT animal health business, expanding its global vaccine portfolio and boosting swine innovation >
Libourne & Dessau 17th. May 2019 - Ceva Santé Animale (“Ceva”) and IDT Biologika GmbH (“IDT”) have reached a provisional agreement for Ceva to acquire IDT’s veterinary biopharmaceutical portfolio and R&D activities, allowing IDT to focus on the manufacture of human biotechnology vaccines and pharmaceuticals for national and international markets. The deal is subject to approval by the Federal Cartel...
WVA/Ceva Global Animal Welfare Awards highlight the special role veterinarians play in protecting the health and welfare of animals >
Veterinarians from around the world, who have made significant contributions to the promotion of animal welfare, have been honoured in the 2019 Global Animal Welfare Awards
Ceva Santé Animale announces the launch of ForcerisTM, the first approved injectable combination of gleptoferron and toltrazuril in Europe >
25th April 2019, Libourne – ForcerisTM received the first marketing authorisation from the European Medicines Agency (EMA) for this innovative combination of gleptoferron and toltrazuril to treat neonatal piglets.
Ceva Poultry Innovation Summit focuses on sharing innovation along the value chain: from day-old chick to precision animal health >
10th April 2019, Libourne - 320 poultry veterinarians, production managers and other key opinion leaders from 50 countries across the world attended the Ceva Poultry Innovation Summit 2019. The event focused on the sharing of pragmatic, scientific and technical information and the latest innovations from the hatchery to precision animal health.
UK Ceva Animal Welfare Awards 2019 – winners announced! >
4 April 2019 The winners of the prestigious Ceva Animal Welfare Awards 2019 have been announced in a glittering ceremony in The Mercian Suite at the Birmingham Conference & Events Centre in Birmingham, following a record-breaking number of nominations of the highest calibre for the third consecutive year.
Ceva Chairman, Marc Prikazsky outlines how the human desire to improve the lives of children will continue to fuel future innovation >
12th March 2019, Libourne - Opening Ceva’s “C the future” Innovation summit ahead of Asia’s leading agricultural show, VIV Asia, Ceva Chairman & CEO, Marc Prikazsky said that the agricultural industry should draw pride and motivation from the work it delivers every day to protect future generations.
The 2019 National Animal Agrobiodiversity Prize: The Bayeux Pig, Pyrenean Goat and Lapin-Chèvre Rabbit Steal the Show >
Libourne, 28 February 2019 – At the International Agricultural Show in Paris, under the patronage of the Ministry of Agriculture, Ceva Santé Animale and the Fondation du Patrimoine presented the “Fondation du Patrimoine National Animal Agrobiodiversity Prize”.
Ceva Japan celebrates 10 years of constant innovation >
26th February 2019, Libourne - Chairman & Ceva CEO Marc Prikazsky visited Ceva Japan to celebrate the 10th anniversary of the company's Yokohama R&D center.